ArticlePloS one2017
Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study).
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Is Population Density Associated with Non-Communicable Disease in Western Developed Countries? A Systematic Review.International journal of environmental research and public health · 2022Pooled it
- Trends in socioeconomic inequalities in preventable lung cancer mortality in three major Spanish cities of the Valencian Community, 2000-2015.Scientific reports · 2026Article
- Article
- Investigating socioeconomic disparities in lung cancer diagnosis, treatment and mortality: an Italian cohort study.BMC public health · 2024Observational
- Risk factors for early mortality of lung cancer patients in France: A nationwide analysis.Cancer medicine · 2022Article
- Machine Learning-Based Analysis of Treatment Sequences Typology in Advanced Non-Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab.JCO clinical cancer informatics · 2022Observational
- Article
- A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer.ERJ open research · 2020Article
- Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study).Therapeutic advances in medical oncology · 2020Article
- Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study).Translational lung cancer research · 2019Article
- Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.BMC cancer · 2018Article
- Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis.Cancer medicine · 2018Article
- Socioeconomic Differences and Lung Cancer Survival-Systematic Review and Meta-Analysis.Frontiers in oncology · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The French healthcare system is a universal healthcare system with no financial barrier to access to health services and cancer drugs. The objective of the study is to investigate associations between, on the one hand, incidence and survival of patients diagnosed with lung cancer in France and, on the other, the socioeconomic deprivation and population density of their municipality of residence. A national, longitudinal analysis using data from the French National Hospital database crossed with the population density of the municipality and a social deprivation index based on census data aggregated at the municipality level. For lung cancer diagnosed at the metastatic stage, one-year and two-year survival was not associated with the population density of the municipality of residence. In contrast, mortality was higher for people living in very deprived, deprived and privileged areas compared to very privileged areas (hazard ratios at two years: 1.19 [1.13-1.25], 1.14 [1.08-1.20] and 1.10 [1.04-1.16] respectively). Similar associations are also observed in patients diagnosed with non-metastatic disease (hazard ratios at two years: 1.21 [1.13-1.30], 1.15 [1.08-1.23] and 1.10 [1.03-1.18] for people living in very deprived, deprived and privileged areas compared to very privileged areas). Despite a universal healthcare coverage, survival inequalities in patients with lung cancer can be observed in France with respect to certain socioeconomic indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.